Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition

被引:29
作者
Mak, Milena Perez [1 ]
da Costa e Silva, Veronica Torres [1 ]
Martin, Regina Matsunaga [2 ]
Lerario, Antonio Marcondes [1 ]
Yu, Luis [1 ]
Gehm Hoff, Paulo Marcelo [1 ]
de Castro Junior, Gilberto [1 ]
机构
[1] Inst Canc Estado Sao Paulo, BR-01246000 Sao Paulo, Brazil
[2] Univ Sao Paulo, Hosp Clin, Fac Med, BR-05403900 Sao Paulo, Brazil
关键词
Tumor-induced osteomalacia; Prostate cancer; Bone metastasis; Hypophosphatemia; FGF23; FIBROBLAST-GROWTH-FACTOR-23;
D O I
10.1007/s00520-012-1474-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor-induced osteomalacia (TIO) is a paraneoplastic bone mineral disturbance related to fibroblast growth factor 23 (FGF23) overproduction by the tumor, usually from mesenchymal origin. Such condition leads to high phosphate renal wasting and, consequently, to cumbersome symptoms as weakness, bone pain, and fractures. Case report. We report a case of an advanced castration-refractory prostate cancer patient, which developed severe hypophosphatemia with elevated phosphate excretion fraction. TIO was suspected, and increased levels of FGF23 reinforced such diagnosis. The patient died 4 months after being diagnosed with TIO. This case suggests that TIO has a dismal prognosis in prostate cancer patients. The clinical oncology community must be aware about such disturbance that can be present in those patients with weakness, bone pain, and hypophosphatemia.
引用
收藏
页码:2195 / 2197
页数:3
相关论文
共 10 条
[1]   Difficult diagnostic cases - Case 3. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan [J].
Auethavekiat, P ;
Roberts, JR ;
Biega, TJ ;
Toney, MO ;
Christensen, RS ;
Belnap, CM ;
Berenberg, JL .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3626-3628
[2]   Tumor-induced osteomalacia [J].
Chong, William H. ;
Molinolo, Alfredo A. ;
Chen, Clara C. ;
Collins, Michael T. .
ENDOCRINE-RELATED CANCER, 2011, 18 (03) :R53-R77
[3]   Clinical features of metastatic bone disease and risk of skeletal morbidity [J].
Coleman, Robert E. .
CLINICAL CANCER RESEARCH, 2006, 12 (20) :6243S-6249S
[4]   Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia [J].
Cotant, Casey L. ;
Rao, Panduranga S. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (06) :1033-1036
[5]   Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [J].
Fizazi, Karim ;
Carducci, Michael ;
Smith, Matthew ;
Damiao, Ronaldo ;
Brown, Janet ;
Karsh, Lawrence ;
Milecki, Piotr ;
Shore, Neal ;
Rader, Michael ;
Wang, Huei ;
Jiang, Qi ;
Tadros, Sylvia ;
Dansey, Roger ;
Goessl, Carsten .
LANCET, 2011, 377 (9768) :813-822
[6]   OSTEOMALACIA AND CARCINOMA OF PROSTATE WITH MAJOR REDISTRIBUTION OF SKELETAL CALCIUM [J].
HOSKING, DJ ;
CHAMBERLAIN, MJ ;
SHORTLANDWEBB, WR .
BRITISH JOURNAL OF RADIOLOGY, 1975, 48 (570) :451-456
[7]   Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. [J].
Jonsson, KB ;
Zahradnik, R ;
Larsson, T ;
White, KE ;
Sugimoto, T ;
Imanishi, Y ;
Yamamoto, T ;
Hampson, G ;
Koshiyama, H ;
Ljunggren, Ö ;
Oba, K ;
Yang, IM ;
Miyauchi, A ;
Econs, MJ ;
Lavigne, J ;
Jüppner, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1656-1663
[8]   Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management [J].
Pelger, RCM ;
Lycklama, GAB ;
Nijeholt, A ;
Papapoulos, SE ;
Hamdy, NAT .
BONE, 2005, 36 (01) :1-5
[9]   Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer [J].
Saad, F ;
Gleason, DM ;
Murray, R ;
Tchekmedyian, S ;
Venner, P ;
Lacombe, L ;
Chin, JL ;
Vinholes, JJ ;
Goas, JA ;
Zheng, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) :879-882
[10]   ONCOGENIC OSTEOMALACIA - EVIDENCE FOR A HUMORAL PHOSPHATURIC FACTOR [J].
WILKINS, GE ;
GRANLESSE, S ;
HEGELE, RG ;
HOLDEN, J ;
ANDERSON, DW ;
BONDY, GP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (05) :1628-1634